MedChemica

New OpenBind consortium to make the UK a leader in AI-driven drug discovery-slashing the cost of drug discovery & development.. & MedChemica are at the heart of it!
Click for the full gov.uk article and direct quote from our Technical Director @griffen-ed.bsky.social
www.gov.uk/government/n...

Opinion: How patents can serve the common good We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that

Interesting piece from colleagues at @dndi.org and @medchemica.com on maximizing the potential for broad #access to #medicines being developed as #public #goods
—
#GlobalHealth #Equity #IP #Patents #Licensing
—
cen.acs.org/pharmaceutic...

ACS talk 4181593 - Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals Presented by Ed Griffen Part of the session "Developing Countermeasures for Viruses of Pandemic Potential" Room: Digital Session (Digital Meeting) Overview: The COVID-19 pandemic was a stark reminder that a barren global antiviral pipeline has grave humanitarian consequences. Pandemics could be prevented, in principle, by accessible, easily deployable broad-spectrum oral antivirals. Here we report the discovery of a family non-peptidomimetic spirolactams that target critical pathogenic coronaviridae including SARS-CoV-2 and MERS-CoV. As part of the ASAP AViDD centre(www.asapdiscovery.org) we expanded the work of the COVID Moonshot's drug discovery campaign targeting the SARS-CoV-2 main protease to deliver orally active compounds with promising in vivo profiles. Using a combination of active learning based medicinal chemistry, alchemical free energy calculations and structure-based design we were able to extend the coronavirus spectrum and optimise the ADMET properties of the series leading to the first public disclosure of the preclinical candidate.

Lead medicinal chemist Ed Griffen (@griffen-ed.bsky.social) will be disclosing the new ASAP MERS-CoV/SARS-CoV-2 oral antiviral at @acs.org on Tue 25 Mar! Tune in to this virtual session to hear about its discovery and development!

acs.digitellinc.com/live/34/sess...

Enamine Ltd | @medchemica.com | PostEra | @jchodera.bsky.social | @diamondlightsource.bsky.social | @mountsinainyc.bsky.social | Weizmann Institute

📢Important announcement! Today, the @asapdiscovery.bsky.social consortium disclosed the structure of our preclinical candidate, ASAP-0017445, a promising broad-spectrum antiviral with potent activity against SARS-CoV2 and other viruses belonging to the same family. (1/10)

5 weeks to go🚀

@griffen-ed.bsky.social is presenting at the @conscience-network.bsky.social Symposium. Talk Title; "Balancing Open Science and Intellectual Property to Discover and Develop Medicines” @asapdiscovery.bsky.social

Register now: conscience.ca/symposium202...

5 weeks to go! 🚀
Dr @griffen-ed.bsky.social is presenting at the ACS Spring Meeting & Expo. Talk Title; “Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals." @asapdiscovery.bsky.social @acs.org #ACSSpring2025

Click to register 🔗 www.acs.org/meetings/acs...

3 weeks to go🚀
@griffen-ed.bsky.social is presenting at #ICAR2025 the highlights of the discovery, in vitro and in vivo profile of the ASAP AViIDD Center’s pre-clinical candidate for treating 6 lethal coronavirus infections: ASAP-0017445. Register now 🔗 lnkd.in/gbBRZSz2 @asapdiscovery.bsky.social

Who is attending the 'Chemist In Industry' SCI conference at Alderley Park tomorrow? Our very own Dr @aldossetter.bsky.social is presenting an insightful talk on ‘Addressing ‘The Big Two.’ – Intrigued? You should be!
See you all there!

#SCI #ChemistInIndustry #DrugDiscovery #DrugDesign

@thesgc.bsky.social @medchemica.com @asapdiscovery.bsky.social

Don't miss our very own Dr Ed Griffen @griffen-ed.bsky.social giving a talk today at the AViDD Open Science Forum...